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Postoperative pain and early quality of life after
radiofrequency ablation and mechanochemical
endovenous ablation of incompetent great
saphenous veins
Ramon R. J. P. van Eekeren, MD,a Doeke Boersma, MD,b Vincent Konijn, MD,a
Jean Paul P. M. de Vries, MD, PhD,b and Michel M. J. P. Reijnen, MP, PhD,a Arnhem and Nieuwegein,
The Netherlands
Objective: Thermal ablative techniques of varicose veins carry a risk of heat-related complications, including postoperative
pain. Mechanochemical endovenous ablation (MOCA) might avoid these complications and reduce postoperative pain
because of the absence of thermal energy. This study evaluated postoperative pain and quality of life after radiofrequency
ablation (RFA) and MOCA for great saphenous vein (GSV) incompetence.
Methods: Sixty-eight patients with unilateral GSV incompetence were treated with either RFA or MOCA in this
prospective observational study. Patients monitored their pain for the first 14 postoperative days on a 100-mm visual
analog scale (VAS). They also completed the general (RAND 36-Item Short-Form Health Survey) and disease-specific
(Aberdeen Varicose Vein Questionnaire) quality of life questionnaires before and 6 weeks after treatment.
Results: Patients treated withMOCA reported significantly less postoperative pain than patients treated with RFA during
the first 14 days after treatment (4.8  9.7 mm vs 18.6  17.0 mm; P < .001) (mean VAS over 14 days). The lower
postoperative pain score was associated with a significantly earlier return to normal activities (1.2 1.8 vs 2.4 2.8 days;
P  .02) and work resumption (3.3  4.7 vs 5.6  5.8 days, respectively; P  .02). At 6 weeks, patients in both groups
perceived an improved change in health status and an improved disease-specific quality of life.
Conclusions: MOCA is associated with significantly less postoperative pain, faster recovery, and earlier work resumption
compared with RFA in the treatment of GSV incompetence. MOCA and RFA are both related to a rapid improvement
in quality of life. ( J Vasc Surg 2013;57:445-50.)
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tVaricose veins are a common medical problem with
overall prevalence of 20% to 60%.1 Chronic venous insuffi-
ciency may have a major effect on patients’ health-related
quality of life in advanced stages of disease, leading to
significant costs in total health care resources.2,3 With
occlusion rates over 90%, as reported for endovenous laser
ablation (EVLA) and radiofrequency ablation (RFA) in
prospective trials,4-6 more emphasis is placed on secondary
outcome measures, such as postoperative pain, complica-
tions, quality of life, and return to normal activities. Ran-
domized studies have reported significantly lower postop-
erative pain after RFA compared with EVLA.7,8 These
studies, however, may have been biased by the choice of
wavelengths and a difference in the fibers used.
Mechanochemical endovenous ablation (MOCA) is a
recently introduced treatment that combines mechanical
damage of the venous intimal layer with the dispersion of a
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http://dx.doi.org/10.1016/j.jvs.2012.07.049iquid sclerosant. The use of tumescent anesthesia is not
ecessary because no heat is used. The first studies of this
echnique have shown that MOCA is a safe and feasible
ethod for treating great saphenous vein (GSV) incompe-
ence with promising short-term results.9,10 Because heat is
ot used as themechanism of action, the risk of heat-related
omplications, including postoperative pain is considered
o be lower. The present study assessed the postoperative
ain and quality of life in patients treated with RFA or
OCA.
ETHODS
Patients. The study included 68 consecutive patients,
reated between January and December 2011 with RFA or
OCA. All were diagnosed with unilateral symptomatic
SV incompetence, and were treated in the Rijnstate Hos-
ital, Arnhem, The Netherlands. Patients treated with
OCA were also included in a prospective registry study
NCT01459263 at clinical.trials.gov). The regional medi-
al ethics committee approved the study. Patients were
ncluded after signing the informed consent form in this
rospective observational trial. Patients, who did not want
o be treated with MOCA, were routinely offered treat-
ent with RFA. All patients had primary GSV incompe-
ence, as demonstrated by duplex imaging, performed by
wo certified vascular practitioners. Reflux was defined as a
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February 2013446 van Eekeren et alretrograde flow of 0.5 seconds after calf compression
measured with the patient upright.
Eligibility criteria were age over 18 years, C2 to C6
varicose veins and primary GSV incompetence. Exclusion
criteria included pregnancy and lactation, the use of anti-
coagulants, previous surgical treatment of varicose veins or
history of deep venous thrombosis. Allergy to polidocanol
was a contra-indication for MOCA.
Treatment. Both treatments were performed under
local anesthesia by a specialized team consisting of a vascu-
lar surgeon and vascular practitioner. Patients were treated
as outpatients in daily care. No sedation or antibiotics were
given.
MOCA was performed using the ClariVein catheter
(Vascular Insights, Madison, Wisc), as previously de-
scribed.9 Briefly, a Seldinger technique was used to intro-
duce a 4F introducer sheath into the GSV, and the
ClariVein catheter was positioned with the tip of the dis-
persion wire 0.5 cm distal of the saphenofemoral junction
(SFJ) under ultrasound guidance. After the tip was properly
positioned, the wire was activated for a few seconds to
induce spasm of the proximal vein. Then, the activated
catheter with rotating tip was steadily withdrawn at 1 cm
every 7 seconds, simultaneously dispersing liquid polido-
canol (Aethoxysklerol; Kreussler Pharma, Wiesbaden, Ger-
many) to the damaged vein wall. The proximal 10 to 15 cm
was treated with 2 mL polidocanol 2% and the remaining
vein with polidocanol 1.5%. The total amount of liquid
sclerosant used was determined by the diameter of the
varicose vein near the SFJ and length of GSV.
In patients treated with RFA, a 6F introducer sheath
was inserted in the GSV under ultrasound guidance using a
Seldinger technique. Then, the VNUS ClosureFAST-
catheter (VNUS Medical Technologies, Sunnyvale, Calif)
was introduced with the tip of the catheter located 2 cm
below the SFJ. Subsequently, tumescent anesthesia was
applied using normal saline containing 1% lidocaine with
epinephrine. After proper positioning of the catheter tip
was confirmed, the GSV was ablated in 7 cm segments
during a 20-second treatment cycle. The temperature was
maintained at 120° during withdrawal of the catheter by
using a feedback system at the heating source.
After the procedures, patients were discharged with
instructions to wear a compression stocking (30-40 mm
Hg) for 2 weeks. Patients were instructed to use analgesics
only when they experienced postoperative pain. No stan-
dard analgesics were prescribed. No concomitant phlebec-
tomies or sclerotherapy were performed. Treatment time
was defined as duration of the treatment starting with
puncturing the vein and ending with removal of the cath-
eter.
Assessment. Patients were examined during the out-
patient visit by a vascular surgeon, who recorded their
CEAP classification11 and Venous Clinical Severity Score
(VCSS).12 Before the procedure, patients were asked to
complete the Dutch versions of the RAND-36-Item Short-
FormHealth Survey (RAND-36)13 and the Aberdeen Var-
icose Vein Questionnaire (AVVQ),14 to observe the gen- bral and disease-specific quality of life, respectively. The
utch version of RAND-36 covers health status in eight
imensions: physical functioning, social functioning, role
imitations due to physical health problems and emotional
roblems, general mental health, vitality, bodily pain, and
eneral health perceptions. Also included is one item that
rovides an indication of perceived changes in health. A
igh score indicates good health status.
At the end of the procedure patients marked their pain
erception on a 100-mm visual analog scale (VAS). Proce-
ural pain was defined as the amount of pain patients
xperienced during the procedure. Afterward patients were
nstructed to complete a 14-day diary card to record the
evel of pain on a 100-mm VAS. On the diary card, patients
ere also asked to provide information about returning to
ormal activities and the amount of analgesics used was
ecorded. The dosage of medication was not listed. At the
-week follow-up, RAND-36 and AVVQ were completed
gain, and a vascular surgeon assessed the VCSS.
Statistical analysis. The primary end point of this
tudy was postoperative pain. A sample size calculation was
erformed based on the assumption that MOCA would
educe postoperative pain during the first 3 days by 50%
ompared with RFA. To describe a significant difference,
4 patients were necessary in each group.
Intergroup analysis was done using the Student t-test
r Mann-WhitneyU test for continuous data and the 2 or
isher exact test for categoric data. Variables are presented
s means standard deviation (SD) if distributed paramet-
ically, or as median with interquartile range (IQR, 25th to
5th percentiles) if distributed nonparametrically. Two-
ided significance was set at P .05. The primary end point
as analyzed using the Mann-Whitney U test. Analysis of
ain was performed using repeated measurements design.
ifferences in scores of the AVVQ, RAND-36, and VCSS
efore and at 6 weeks after treatment were tested using the
ilcoxon signed-rank test, for single group analysis. The
ann-WhitneyU test was used to test differences in change
etween both groups.
Statistical analyses were performed using SPSS 15.0
oftware (SPSS Inc, Chicago, Ill). A statistician supervised
ll analyses.
ESULTS
During the study period, 68 patients (25 men, 43
omen) were treated, 34 in each group, and all completed
heir 6-week follow-up assessment. Patients were a mean
ge of 58  17 years. Patient characteristics are summa-
ized in Table I. There were no significant differences
etween the groups regarding demographic data, CEAP
lassification, preoperative VCSS, and initial AVVQ. The
reated GSV was significantly wider at the SFJ in the RFA
roup than in theMOCA group (P .03). Treatment time
as significantly shorter in theMOCA group (P .02). No
ajor complications occurred in either group, and there
as no difference in the incidence of minor complications
etween the two groups (Table II).
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Volume 57, Number 2 van Eekeren et al 447After 6 weeks, the median VCSS significantly decreased
in both groups, from 3.0 (IQR, 2.75-5.25) to 1.0 (IQR,
1.0-2.0) in the MOCA group (P  .001) and from 4.0
(IQR, 3.0-7.0) to 3.0 (IQR, 1.25-3.75) in the RFA group
(P  .001). VCSS improvement was similar between
groups (P  .21). Although the VCSS improved in most
patients, VCSS deteriorated in five patients at 6 weeks after
treatment; one in the MOCA group and four in the RFA
group (Fig 1). There were three patients with reported
postoperative pain after 2 weeks, one patient with a throm-
bophlebitis, and one patient with induration. The median
Table I. Patient characteristics and technical data
MO
(n 
Age, years 57.2 
Sex
Male 12 (35
Female 22 (65
BMI 25.6 
CEAP
C1 1 (3%
C2 16 (47
C3 8 (23
C4 8 (23
C5-6 1 (3%
AVVQ 7.1 (5.
VCSS 3.0 (2.
GSV diameter, mm 5.7 
Length of vein ablated, cm 45.3 
Time of procedure, minutes 13.0 (10
Procedural pain (0-100 mm VAS) 22 
Number RFA cycles —
Amount of polidocanol, mg 118 
Total volume of polidocanol, mL 6.9 
AVVQ, Aberdeen Varicose Vein Questionnaire; BMI, body mass index; CE
saphenous vein; MOCA, mechanochemical endovenous ablation; RFA, rad
Score.
aStudent t-test.
b2 test.
cMann-Whitney U test.
Table II. Complications in the first 6 weeks after MOCA
and RFA
MOCA RFA
P value(n  34) (n  34)
Major complications
Deep venous thrombosis 0 0
Pulmonary embolism 0 0
Skin burn 0 0
Minor complications
Hematoma 2 (6%) 4 (12%) .67a
Paresthesia 0 0
Thrombophlebitis 0 2 (6%) .49a
Induration 4 (12%) 8 (24%) .20b
Hyperpigmentation 3 (9%) 3 (9%) 1.0a
MOCA, Mechanochemical endovenous ablation; RFA, radiofrequency ab-
lation.
aFisher exact test.
b2 test.deterioration in VCSS was 1.0 (IQR, 1.0-2.0). 1Postoperative pain. The mean procedural pain dur-
ng treatment was 22  16 mm for MOCA and 27  15
m for RFA (P  .16) on the 0 to 100-mm VAS. The
rogress of postoperative pain is shown in Fig 2. At each
ostoperative day, the difference between groups was sta-
istically significant. Patients receivingMOCA reported less
ain over the first 3 days, with mean pain of 6.2 9.2 mm
or MOCA and 20.5 25.5 mm for RFA (P .004). The
ean postoperative pain per day during the first 14 days
fter treatment was 4.8 9.7 mm in theMOCA group and
RFA
P value(n  34)
2 58.0  17.8 .85a
13 (38%) .80b
21 (62%)
26.6  4.1 .33a
0 (0%) .31b
9 (26%)
10 (30%)
14 (41%)
1 (3%)
) 9.5 (4.5-16.4) .17c
25) 4.0 (3.0-7.0) .09c
6.8  2.4 .03a
46.8  10.1 .54a
.0) 14.5 (12.0-17.3) .02c
27  15 .16a
7.7  1.4
—
—
linical Etiologic Anatomical Pathophysiological classification; GSV, great
uency ablation; VAS, visual analog scale; VCSS, Venous Clinical Severity
ig 1. Assessment of the Venous Clinical Severity Score (VCSS) 6
eeks after treatment with mechanochemical endovenous ablation
MOCA) and radiofrequency ablation (RFA).CA
34)
15.
%)
%)
3.9
)
%)
.5%)
.5%)
)
3-9.2
75-5.
1.6
9.7
.0-15
16
22
1.9
AP, C
iofreq8.6 17.0 mm in the RFA group (P .001). Thrombo-
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February 2013448 van Eekeren et alphlebitis and induration were associated with more postop-
erative pain in both groups.
Information about the number of days, in which pa-
tients used analgesics (mostly paracetamol or ibuprofen),
was available in 60 patients (88%). Patients in the MOCA
group used postoperative analgesics for a mean of 0.5 1.5
days compared with 2.8 4.2 days in had significantly less
days, in which postoperative analgesics were used than in
the RFA group, which was a significant difference (P 
.008).
Quality of life. Six weeks after treatment, the AVVQ
improved significantly in both groups, from 7.1 (IQR,
5.3-9.2) to 5.0 (IQR, 3.0-8.5) in the MOCA group (P 
.006) and from 9.5 (IQR, 4.5-16.4) to 4.5 (IQR, 1.5-
11.2) in the RFA group (P  .002). The difference in
AVVQ change between the groups was not statistically
significant (P  .17).
Comparison of RAND-36 scores before and at 6 weeks
after treatment with MOCA and RFA showed that health
status significantly improved in two dimensions for MOCA
(physical functioning and role limitations physical). For
RFA there was an improvement in bodily pain after 6
weeks. No deterioration in quality of life was observed.
Patients in both groups perceived an improved change in
health status (Table III).
Return to normal activities. The time to return to
normal activities was 1.0 day (IQR, 0-1.0) in the MOCA
group and 1.0 day (IQR, 1.0-3.0) in the RFA group, which
was significantly longer (P  .01). The median time to
Fig 2. Mean postoperative pain scores on a 0 to 100 mm visual
analogue scale for 14 days after mechanochemical endovenous
ablation (MOCA) and radiofrequency ablation (RFA). CI, Confi-
dence interval; VAS, visual analog scale.work resumption for employees was significantly shorter in lhe MOCA group than in the RFA group (P  .02),
espectively, 1.0 days (IQR, 1.0-3.75) vs 2.0 days (IQR,
.0-7.0).
ISCUSSION
This study has demonstrated that postoperative pain is
ignificantly lower after MOCA compared with RFA, cor-
esponding to a 74% reduction in pain for the first 14
ostoperative days. MOCA was also associated with a sig-
ificantly faster return to normal activities and work re-
umption.
Whereas occlusion rates over 90% are constantly re-
orted after endovenous treatment, secondary outcome
easures of treatment, such as postoperative pain, return to
ormal activities and health-related quality of life become
ore important to determine the optimal endovenous
reatment for patients with varicose veins.15,16 Several stud-
es have analyzed postoperative pain after thermal endovenous
blation, foam sclerotherapy, and surgical stripping. Rasmus-
en et al reported significantly less postoperative pain in pa-
ients treated with RFA (1.21) and foam sclerotherapy
1.60) than those treated with EVLA (2.58) and surgical
tripping (2.25).16 The observed pain was presented as
ean pain during the first 10 days on a 0 to 10 cm VAS.
ther randomized studies also confirmed the superiority of
FA over EVLA in postoperative pain.7,8,17 The postoper-
tive pain in patients treated with RFA in this study is
onsistent with those reports. However, results of postop-
rative pain are difficult to compare, while outcomes of
ostoperative pain have been valued in various ways. Most
eports on postoperative pain after varicose vein treatment
se a VAS to evaluate postoperative pain, but a validation
tudy of different pain rating scales has never been per-
ormed for this specific subject. Evidence supports the
eliability and validity of most pain intensity scales.18 The
uthors advocate a uniform use of outcome measures for
ostoperative pain.
The postoperative pain in patients treated with MOCA
as consistent with our previous report. In a safety study,
e found that the mean postoperative pain on the first day
as 9 mm on a 0 to 100 mm VAS.9 The score decreased to
mean of 2mm, 7 days afterMOCA. Themain objective of
his study was to evaluate postoperative pain and early
uality of life, not to observe anatomical success. However,
arger comparative studies are needed to assess the long-
erm efficacy of MOCA. Elias et al reported a 96.7% occlu-
ion rate at 260 days in patients treated withMOCA.10 The
bserved differences in postoperative pain in the present
tudy may be explained by the different mechanisms of
ction. Heating the vein and its surrounding tissue with
FA causes endothelial denudation, collagen denaturation,
nd vein closure at temperatures of 120°C.19 Perforation of
eins and heating of surrounding perivenous tissue is
hought to be associated with (prolonged) postoperative
ain.
MOCA combines mechanical damage to the endothe-
ium of the vein wall with the infusion of a sclerosant. The
iquid sclerosant produces irreversible damage to the ve-
A
h
v
a
c
s
R
c
q
c
t
w
p
e
i
t
r
o
d
p
p
t
c
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 van Eekeren et al 449nous endothelium. The cellular membranes of the endo-
thelium are damaged, creating denudation of the endothe-
lium and endofibrosis. Finally, this causes venous obliteration
and thrombus development.20 Damage of the endothelium
depends on the concentration of sclerosant. The purpose of
the mechanical damage is fourfold: (1) promoting the
coagulation activation by minimal mechanical damage to
the endothelium, (2) inducing a vasospasm that reduces the
diameter of the vein, (3) increasing the action of sclerosant
by an increase in surface, and (4) ensuring an even distri-
bution of the sclerosant at the endothelium. A recent study
showed that adding mechanical balloon catheter injury to
standard foam sclerotherapy increased endothelial cell
loss.21 No (in vivo) histologic studies on MOCA are to
date, but the authors hypothesize that the rotating wire also
increases endothelial cell loss. Moreover, endothelial cell
loss and damage to the media are significantly greater with
sodium tetradecyl sulfate compared with polidocanol.22 In
this study polidocanol was used as single sclerosant regis-
tered in The Netherlands.
Although the VAS was threefold lower in the MOCA
group, the procedural pain was not significantly different
between the groups. This may have been caused by the
small sample size, because the study was powered a reduc-
tion of 50% in the postoperative course. Previous studies
Table III. Median (IQR) health status scores for patients
(RAND-36)
Preoperative status
Physical functioning
MOCA 87.5 (71.3-100)
RFA 80 (57.5-95)
Social functioning
MOCA 93.8 (78.1-100)
RFA 87.5 (62.5-100)
Role - physical
MOCA 100 (50-100)
RFA 75 (0-100)
Role - emotional
MOCA 100 (100-100)
RFA 100 (66.7-100)
Mental health
MOCA 84 (70-92)
RFA 76 (64-90)
Vitality
MOCA 70 (45-85)
RFA 65 (47.5-80)
Bodily pain
MOCA 84.7 (67.3-100)
RFA 67.3 (39.7-79.6)
Health perception
MOCA 70 (55-90)
RFA 65 (50-75)
Health change
MOCA 50 (50-50)
RFA 50 (25-50)
IQR, Interquartile range; MOCA, mechanochemical endovenous ablation
ablation.
aWilcoxon signed-rank test.
bMann-Whitney U test.have not assessed procedural pain as an outcome measure. tdding tumescence anesthesia to a standard treatment,
owever, does not seem to contribute to a clinically rele-
ant increase in procedural pain. In addition, tumescence
nesthesia is time-consuming, as reflected by the signifi-
antly longer treatment time with RFA. In the present
tudy, tumescence anesthesia was widely applied before the
FA treatment was initiated. Because insufficient tumes-
ent anesthesia may contribute to increased pain, the ade-
uacy was assessed by duplex ultrasound imaging and by
ontrolling the temperature of the catheter on the monitor.
Patients treated with MOCA needed significantly less
ime to return to normal activities, and the time to resume
ork was also significantly shorter. The observation that
atients treated with MOCA resume their work 1 day
arlier than patients treated with RFA might have a signif-
cant effect on the total health care burden of varicose vein
reatment. This observation urges the initiation of further
andomized studies to confirm the observation.
As assessed by the RAND-36 results, the health status
f patients was improved 6 weeks after MOCA in the
imensions of physical functioning and role limitations
hysical. This suggests that these patients perceived fewer
roblems with their daily physical activities, also related
oward employment. Both groups, however, had a signifi-
ant improvement in perceived health change. In addition,
re and 6 weeks after treatment with MOCA and RFA
weeks P valuea P value intergroupb
(80-100) .02 .21
(57.5-95) .83
(75-100) .77 .72
(75-100) .56
(100-100) .046 .48
(25-100) .875
(100-100) .1 .46
(83.3-100) .68
(68-92) .49 .37
(66-90) .88
(60-85) .14 .42
(55-77.5) .66
(67.4-100) .3 .34
(51-89.7) .025
(60-95) .3 .89
(52.5-80) .52
(50-75) .015 .69
(50-75) .035
D-36, RAND-36-Item Short-Form Health Survey; RFA, radiofrequencybefo
6
95
80
100
87.5
100
75
100
100
84
80
75
65
89.8
69.4
75
70
50
50
; RANhe disease-specific quality of life improved in both groups,
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1
1
1
1
1
1
1
1
2
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ing quality of life are in line with existing reports. However,
differences in quality of life are usually observed 1 year after
treatment.16
The present trial had some limitations. First, the study
has a small population, although the expected 50% reduc-
tion in postoperative pain was achieved. Second, the study
did not document other variables that can be associated
with postoperative pain, such as depth of the vein from skin
level, amount of tumescence fluid, quality of tumescence
anesthesia, and incidence of perforation of the treated vein.
The quality of tumescence anesthesia, in particular, is a
complex parameter to observe, whereas we presume this
parameter is the most important factor of pain after endo-
thermal ablation. Finally, as with all nonrandomized stud-
ies, results are more susceptible to selection and measure-
ment biases.
In conclusion, MOCA is associated with significantly
less postoperative pain and a faster recovery and work
resumption, compared with RFA in the treatment of great
saphenous incompetence. These observations should be
confirmed in a randomized controlled trial. Outcomes of
postoperative pain after endovenous ablative techniques for
varicose veins may be helpful for clinicians in the decision
making for optimal treatment.
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